Zura Bio (NASDAQ:ZURA) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Zura Bio Limited (NASDAQ:ZURA) saw strong trading volume on Tuesday . Approximately 703,847 shares changed hands during mid-day trading, a decline of 20% from the previous session’s volume of 877,647 shares.The stock last traded at $6.4050 and had previously closed at $6.30.

Wall Street Analyst Weigh In

ZURA has been the topic of several recent research reports. William Blair started coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Monday, July 6th. Guggenheim raised their price target on shares of Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Wedbush lifted their price objective on shares of Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Zura Bio Price Performance

The firm has a fifty day simple moving average of $5.36 and a 200 day simple moving average of $5.39. The company has a market cap of $574.02 million, a price-to-earnings ratio of -5.30 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. Analysts expect that Zura Bio Limited will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Zura Bio

Hedge funds have recently bought and sold shares of the company. Commodore Capital LP bought a new position in Zura Bio in the 1st quarter worth approximately $19,338,000. Siren L.L.C. grew its stake in shares of Zura Bio by 187.3% in the first quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after acquiring an additional 2,434,866 shares during the last quarter. JPMorgan Chase & Co. increased its position in Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares during the period. EcoR1 Capital LLC acquired a new position in Zura Bio during the 1st quarter valued at $7,019,000. Finally, Stempoint Capital LP acquired a new position in Zura Bio during the 1st quarter valued at $4,483,000. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.